全文获取类型
收费全文 | 1362篇 |
免费 | 39篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 1篇 |
妇产科学 | 13篇 |
基础医学 | 226篇 |
口腔科学 | 8篇 |
临床医学 | 40篇 |
内科学 | 200篇 |
皮肤病学 | 15篇 |
神经病学 | 187篇 |
特种医学 | 12篇 |
外科学 | 41篇 |
综合类 | 73篇 |
预防医学 | 29篇 |
眼科学 | 11篇 |
药学 | 380篇 |
中国医学 | 60篇 |
肿瘤学 | 114篇 |
出版年
2023年 | 3篇 |
2022年 | 4篇 |
2021年 | 8篇 |
2020年 | 6篇 |
2019年 | 14篇 |
2018年 | 17篇 |
2017年 | 24篇 |
2016年 | 9篇 |
2015年 | 22篇 |
2014年 | 52篇 |
2013年 | 86篇 |
2012年 | 71篇 |
2011年 | 117篇 |
2010年 | 99篇 |
2009年 | 92篇 |
2008年 | 103篇 |
2007年 | 118篇 |
2006年 | 92篇 |
2005年 | 83篇 |
2004年 | 90篇 |
2003年 | 83篇 |
2002年 | 57篇 |
2001年 | 26篇 |
2000年 | 31篇 |
1999年 | 24篇 |
1998年 | 18篇 |
1997年 | 9篇 |
1996年 | 9篇 |
1995年 | 18篇 |
1994年 | 9篇 |
1993年 | 6篇 |
1992年 | 7篇 |
1991年 | 2篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1985年 | 1篇 |
排序方式: 共有1414条查询结果,搜索用时 15 毫秒
1.
目的观察阿霉素(DOX)对坐骨神经慢性缩窄性损伤(CCI)模型大鼠的镇痛作用,并从形态学及组织凋亡蛋白的角度对其机制进行分析。方法将SD大鼠随机分为4组:假手术组(Sham)、CCI模型组(Model)、假手术+阿霉素5 mg·kg-1组(Sham+DOX)、CCI模型+阿霉素5 mg·kg-1组(Model+DOX)。造模成功后,各组采用尾静脉注射的方式给药,Sham组和Model组给予等量生理盐水,检测各组大鼠机械痛阈值和热痛阈值。在行为学检测结束后,即手术后d 15取大鼠右侧L4-5DRG,观察DRG细胞形态、超微结构及DOX的分布情况,采用Western blot法测定DRG组织中Bax、Bcl-2、PKCɑ、PKCδ及PKCε的蛋白表达。结果静脉注射DOX可在DRG组织检测到其自发荧光表达。与Sham组相比,Sham+DOX组痛阈值在整个观察期未见差别,而Model组在术后d 7痛阈值明显降低。与Model组相比,Model+DOX组的痛阈值在给药后明显回升,并表现出DRG细胞明显损伤,Bax/Bcl-2升高以及PKCδ、PKCε的蛋白表达量降低等现象。结论 DOX静脉注射可以到达并蓄积于DRG组织,明显减轻CCI大鼠的疼痛反应,这一作用与其降低PKCδ和PKCε的蛋白表达,诱导DRG的凋亡有关。 相似文献
2.
Future therapy of diabetes mellitus 总被引:2,自引:0,他引:2
For reaching near normal glycemic control, multiple daily insulin injections are necessary, although subcutaneous insulin therapy cannot get the physiological profile, results in hypoglycemia, weight gain, peripheral hyperinsulinemia, and may not be accepted for painful injections. Glucagon-like peptide 1(GLP-1) analogs and alternative routes of insulin, especially oral (enteric-gastrointestinal, inhaled) route, are most promising and attractive now. Biotechnology and biochemistry will make it possible to overcome several disadvantages of low absorption, short half-life, low bioavailability, and many clinical trials are now in progress. We will show the review of these drugs and another candidate for the treatment of diabetic complications, protein kinase C inhibitor. 相似文献
3.
4.
PKC/MEK inhibitors suppress oxaliplatin‐induced neuropathy and potentiate the antitumor effects 下载免费PDF全文
Masanobu Tsubaki Tomoya Takeda Tadahumi Tani Hirotaka Shimaoka Naohiro Suzuyama Kotaro Sakamoto Arisa Fujita Naoki Ogawa Tatsuki Itoh Motohiro Imano Yoshinori Funakami Seiji Ichida Takao Satou Shozo Nishida 《International journal of cancer. Journal international du cancer》2015,137(1):243-250
Oxaliplatin is a key drug commonly used in colorectal cancer treatment. Despite high clinical efficacy, its therapeutic application is limited by common, dose‐limiting occurrence of neuropathy. As usual symptomatic neuropathy treatments fail to improve the patients' condition, there is an urgent need to advance our understanding of the pathogenesis of neuropathy to propose effective therapy and ensure adequate pain management. Oxaliplatin‐induced neuropathy was recently reported to be associated with protein kinase C (PKC) activation. It is unclear, however, whether PKC inhibition can prevent neuropathy. In our current studies, we found that a PKC inhibitor, tamoxifen, inhibited oxaliplatin‐induced neuropathy via the PKC/extracellular signal‐regulated kinase (ERK)/c‐Fos pathway in lumbar spinal cords (lumbar segments 4–6). Additionally, tamoxifen was shown to act in synergy with oxaliplatin to inhibit growth in tumor cells‐implanted mice. Moreover, mitogen‐activated protein kinase kinase (MEK) 1/2 inhibitor, PD0325901, suppressed oxaliplatin‐induced neuropathy and enhanced oxaliplatin efficacy. Our results indicate that oxaliplatin‐induced neuropathy is associated with PKC/ERK/c‐Fos pathway in lumbar spinal cord. Additionally, we demonstrate that disruption of this pathway by PKC and MEK inhibitors suppresses oxaliplatin‐induced neuropathy, thereby suggesting that PKC and MEK inhibitors may be therapeutically useful in preventing oxaliplatin‐induced neuropathy and could aid in combination antitumor pharmacotherapy. 相似文献
5.
Abstract.
Calcium homeostasis is intimately regulated by protein kinase
phosphorylation cascades that are also involved in the induction and maintenance
of cardiac hypertrophy. In addition, the development of cardiac
hypertrophy has been associated with alteration in the activation of the
adrenergic system. Therefore, we investigated the specific role of protein
kinase A (PKA) and C (PKC) on cardiac muscle contractile activity in the
presence and absence of adrenergic stimulation. Isolated left atrial preparations
from sham– and volume overload–induced cardiac hypertrophied rats
were superfused with Tyrode and electrically stimulated at 0.75 Hz. Contraction
was assessed in the basal and pre–stimulated (norepinephrine, 10–9M)
states. Specific inhibitors, KT 5720 for PKA and Ro-32-0432 for PKC, were
used. Peak tension development in left atria from sham–operated rats was
more sensitive to PKC– than PKA–inhibition, whereas this differential sensitivity
was abolished in the hypertrophied hearts. This difference was mainly
due to an increase in the role of PKA in the contractile response. Developed
peak tension by left atria from shunt rats was higher than that from sham rats,
but when expressed to relative tissue mass, hypertrophied muscle showed
weaker contraction than that from the sham group. In addition, the left atrial
velocity of contraction in the sham is PKA–sensitive, while that of the shunt
is PKC–sensitive. Furthermore, the velocity of relaxation shows dependency
on both protein kinases, with PKC having a greater effect than PKA in the
hypertrophied group. NE increased the PTD and the velocity of contraction
(+dT/dt) through PKA and PKC dependent mechanisms, without affecting
the velocity of relaxation (–dT/dt) in atrial muscle from sham rats. In contrast,
during eccentric hypertrophy NE effectively reduced PTD as well as the
–dT/dt through a PKC–dependent mechanism. The present study demonstrates
that during early development of moderate eccentric cardiac hypertrophy
there is: (1) a reduced specific peak tension developed due to an imbalance
in the PKA and PKC activation; (2) a change in the protein kinase
dependence of the velocity of contraction and relaxation from PKA to PKC
with atrial hypertrophy; and (3) a negative inotropic response to adrenergic
receptor stimulation. These functional responses may play a critical role in
the cardiac performance during the progression of eccentric cardiac hypertrophy
into the decompensated phase and heart failure. 相似文献
6.
Anika Mann Susann Illing Elke Miess Stefan Schulz 《British journal of pharmacology》2015,172(2):311-316
The efficiency of μ-opioid receptor signalling is tightly regulated and ultimately limited by the coordinated phosphorylation of intracellular serine and threonine residues. Here, we review and discuss recent progress in the generation and application of phosphosite-specific μ-opioid receptor antibodies, which have proved to be excellent tools for monitoring the spatial and temporal dynamics of receptor phosphorylation and dephosphorylation. Agonist-induced phosphorylation of μ-opioid receptors occurs at a conserved 10 residue sequence 370TREHPSTANT379 in the receptor''s carboxyl-terminal cytoplasmic tail. Diverse opioids induce receptor phosphorylation at S375, present in the middle of this sequence, but only high-efficacy opioids have the ability to drive higher order phosphorylation on flanking residues (T370, T376 and T379). S375 is the initiating residue in a hierarchical phosphorylation cascade. In contrast, agonist-independent heterologous μ-opioid receptor phosphorylation occurs primarily at T370. The combination of phosphosite-specific antibodies and siRNA knockdown screening also facilitated the identification of relevant kinases and phosphatases. In fact, morphine induces a selective S375 phosphorylation that is predominantly catalysed by GPCR kinase 5 (GRK5), whereas multisite phosphorylation induced by high-efficacy opioids specifically requires GRK2/3. By contrast, T370 phosphorylation stimulated by phorbol esters or heterologous activation of Gq-coupled receptors is mediated by PKCα. Rapid μ-opioid receptor dephosphorylation occurs at or near the plasma membrane and is catalysed by protein phosphatase 1γ (PP1γ). These findings suggest that there are distinct phosphorylation motifs for homologous and heterologous regulation of μ-opioid receptor phosphorylation. However, it remains to be seen to what extent different μ-opioid receptor phosphorylation patterns contribute to the development of tolerance and dependence in vivo.
LINKED ARTICLES
This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2 相似文献7.
Emanuela Corsini Valentina Galbiati Antonella Pinto Annalisa Davin Letizia Polito Antonio Guaita Marco Racchi 《Oncotarget》2015,6(9):6524-6534
Aims of this study were to investigate the ability of RACK1 pseudosubstrate alone or in combination with classical immune stimuli to activate human leukocytes, and to restore age-associated immune defects.A total of 25 donors (17 old donors, 77–79 yrs; 8 young donors, 25–34 yrs) were enrolled. To evaluate the effect of RACK1 pseudosubstrate on cytokine production and CD86 expression the whole blood assay was used. Cultures were treated with RACK1 pseudosubstrate in the presence or absence of lipopolysaccharide (LPS) or phytohaemagglutinin (PHA) and incubated for 24 h or 48 h for LPS-induced CD86 expression, TNF-α, IL-6, IL-8, IL-10 production, and PHA-induced IL-4, IL-10, IFN-γ, respectively. RACK1 pseudosubstrate alone induced IL-6, IL-8, and CD86 expression in both young and old donors, and IFN-γ in old donors. In combination with LPS an increase in IL-8, IL-10 and TNF-α was observed, also resulting in restoration of age-associated defective production, while no changes in the other parameters investigated were found.Even if based on a small sample size, these results suggest the possibility to by-pass some of age-associated immune alterations, which may be beneficial in situations were natural immune stimulation is required, and highlight a different role of PKCβ in immune cells activation. 相似文献
8.
Atsushi Ishii Sawa Yasumoto Yukiko Ihara Takahito Inoue Takako Fujita Noriko Nakamura Masaharu Ohfu Yushiro Yamashita Hideo Takatsuka Toshiaki Taga Rie Miyata Masahiro Ito Hiroshi Tsuchiya Taro Matsuoka Tetsuya Kitao Kiyotaka Murakami Wang-Tso Lee Sunao Kaneko Shinichi Hirose 《Brain & development》2013
Purpose: PRRT2 mutations were recently identified in benign familial infantile epilepsy (BFIE) and infantile convulsions with paroxysmal choreoathetosis (ICCA) but no abnormalities have so far been identified in their phenotypically similar seizure disorder of benign convulsions with mild gastroenteritis (CwG), while mutations in KCNQ2 and KCNQ3 have been recognized in benign familial neonatal epilepsy (BFNE). The aim of this study was to identify PRRT2 mutations in infantile convulsions in Asian families with BFIE and ICCA, CwG and BFNE. Methods: We recruited 26 unrelated Japanese affected with either BFIE or non-familial benign infantile seizures and their families, including three families with ICCA. A total of 17 Japanese and Taiwanese with CwG, 50 Japanese with BFNE and 96 healthy volunteers were also recruited. Mutations of PRRT2 were sought using direct sequencing. Results: Heterozygous truncation mutation (c.649dupC) was identified in 15 of 26 individuals with benign infantile epilepsy (52.1%). All three families of ICCA harbored the same mutation (100%). Another novel mutation (c.1012+2dupT) was found in the proband of a family with BFIE. However, no PRRT2 mutation was found in either CwG or BFNE. Conclusions: The results confirm that c.649dupC, a truncating mutation of PRRT2, is a hotspot mutation resulting in BFIE or ICCA regardless of the ethnic background. In contrast, PRRT2 mutations do not seem to be associated with CwG or BFNE. Screening for PRRT2 mutation might be useful in early-stage differentiation of BFIE from CwG. 相似文献
9.
Tzu‐Yu Lin Chih‐Yang Chung Cheng‐Wei Lu Shu‐Kuei Huang Jiann‐Sing Shieh Su‐Jane Wang 《Synapse (New York, N.Y.)》2013,67(9):568-579
Local anesthetics have been widely used for regional anesthesia and the treatment of cardiac arrhythmias. Recent studies have also demonstrated that low‐dose systemic local anesthetic infusion has neuroprotective properties. Considering the fact that excessive glutamate release can cause neuronal excitotoxicity, we investigated whether local anesthetics might influence glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Results showed that two commonly used local anesthetics, lidocaine and bupivacaine, exhibited a dose‐dependent inhibition of 4‐AP‐evoked release of glutamate. The effects of lidocaine or bupivacaine on the evoked glutamate release were prevented by the chelation of extracellular Ca2+ ions and the vesicular transporter inhibitor bafilomycin A1. However, the glutamate transporter inhibitor dl ‐threo‐beta‐benzyl‐oxyaspartate did not have any effect on the action of lidocaine or bupivacaine. Both lidocaine and bupivacaine reduced the depolarization‐induced increase in [Ca2+]C but did not alter 4‐AP‐mediated depolarization. Furthermore, the inhibitory effect of lidocaine or bupivacaine on evoked glutamate release was prevented by blocking the Cav2.2 (N‐type) and Cav2.1 (P/Q‐type) channels, but it was not affected by blocking of the ryanodine receptors or the mitochondrial Na+/Ca2+ exchange. Inhibition of protein kinase C (PKC) and protein kinase A (PKA) also prevented the action of lidocaine or bupivacaine. These results show that local anesthetics inhibit glutamate release from rat cortical nerve terminals. This effect is linked to a decrease in [Ca2+]C caused by Ca2+ entry through presynaptic voltage‐dependent Ca2+ channels and the suppression of the PKA and PKC signaling cascades. Synapse 67:568–579, 2013 . © 2013 Wiley Periodicals, Inc. 相似文献
10.
Jie Shen Lijun Xu Taofeek K. Owonikoko Shi-Yong Sun Fadlo R. Khuri Walter J. Curran Xingming Deng 《Cancer letters》2012
Cigarette smoking, either active or passive, is the most important risk factor in the development of human lung cancer. Mounting evidence indicates that cigarette smoke constituents not only contribute to tumorigenesis but also may increase the spread of cancer in the body. Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is formed by nitrosation of nicotine and has been identified as the most potent carcinogen. NNK, an important component in cigarette smoke, may also promote tumor metastasis by regulating cell motility. Here we found that NNK can induce activation of a functionally interdependent protein kinase cascade, including c-Src, PKCι and FAK, in association with increased migration and invasion of human lung cancer cells. c-Src, PKCι and FAK are extensively co-localized in the cytoplasm. Treatment of cells with α7 nAChR specific inhibitor α-bungarotoxin (α-BTX) blocks NNK-stimulated activation of c-Src, PKCι and FAK and suppresses cell migration and invasion. Intriguingly, NNK enhances c-Src/PKCι and PKCι/FAK bindings, indicating a potential mechanism by which these kinases activate each other. Specific disruption of c-Src, PKCι or FAK expression by RNA interference significantly reduces NNK-induced cell migration and invasion. These findings suggest that NNK-induced migration and invasion may occur in a mechanism through activation of a c-Src/PKCι/FAK loop, which can contribute to metastasis and/or development of human lung cancer. 相似文献